In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor, and BioMarin enters a definitive $4.8 billion agreement to acquire Amicus Therapeutics.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor, and BioMarin enters a definitive $4.8 billion agreement to acquire Amicus Therapeutics.
President Trump has announced that nine additional drug manufacturers will participate in TrumpRx, expanding the scope of the government-facilitated direct-to-patient drug purchasing initiative. The new additions span branded and specialty medicines, underscoring both industry interest and ongoing debates over cost, access, and distribution models.
In oncology deal news, AstraZeneca has signed a $2 billion exclusive licensing agreement with Jacobio Pharma for rights to a next-generation pan-KRAS inhibitor. The collaboration strengthens AstraZeneca’s targeted therapy portfolio and reflects growing global interest in KRAS as a critical oncology target.
And in a major acquisition, BioMarin Pharmaceutical has reached a $4.8 billion definitive agreement to acquire Amicus Therapeutics, enhancing its rare disease pipeline. The deal brings complementary programs in lysosomal storage disorders and other genetic conditions into BioMarin’s portfolio, signaling continued consolidation in the rare disease space.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
